IIQ Stock Overview
INOVIQ Ltd engages in the research, development, and commercialization of diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.56|
|52 Week High||AU$1.50|
|52 Week Low||AU$0.39|
|1 Month Change||1.80%|
|3 Month Change||22.83%|
|1 Year Change||-48.17%|
|3 Year Change||-60.76%|
|5 Year Change||135.42%|
|Change since IPO||-21.53%|
Recent News & Updates
INOVIQ (ASX:IIQ) Is In A Good Position To Deliver On Growth Plans
We can readily understand why investors are attracted to unprofitable companies. For example, although...
We're Hopeful That INOVIQ (ASX:IIQ) Will Use Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
|IIQ||AU Healthcare||AU Market|
Return vs Industry: IIQ underperformed the Australian Healthcare industry which returned -20.1% over the past year.
Return vs Market: IIQ underperformed the Australian Market which returned -10.6% over the past year.
|IIQ Average Weekly Movement||13.0%|
|Healthcare Industry Average Movement||5.3%|
|Market Average Movement||9.6%|
|10% most volatile stocks in AU Market||16.8%|
|10% least volatile stocks in AU Market||4.2%|
Stable Share Price: IIQ is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: IIQ's weekly volatility (13%) has been stable over the past year.
About the Company
INOVIQ Ltd engages in the research, development, and commercialization of diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. The company offers hTERT test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET for capturing and isolating exosomes from liquid biopsy sample. Its cancer diagnostic pipeline includes blood tests in development for ovarian, breast, and other cancers.
INOVIQ Fundamentals Summary
|IIQ fundamental statistics|
Is IIQ overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|IIQ income statement (TTM)|
|Cost of Revenue||AU$3.09m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.071|
|Net Profit Margin||-326.20%|
How did IIQ perform over the long term?See historical performance and comparison
Is IIQ undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for IIQ?
Other financial metrics that can be useful for relative valuation.
|What is IIQ's n/a Ratio?|
Price to Sales Ratio vs Peers
How does IIQ's PS Ratio compare to its peers?
|IIQ PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
SLA SILK Laser Australia
MAP Microba Life Sciences
AHX Apiam Animal Health
Price-To-Sales vs Peers: IIQ is expensive based on its Price-To-Sales Ratio (26x) compared to the peer average (3.5x).
Price to Earnings Ratio vs Industry
How does IIQ's PE Ratio compare vs other companies in the AU Healthcare Industry?
Price-To-Sales vs Industry: IIQ is expensive based on its Price-To-Sales Ratio (26x) compared to the Australian Healthcare industry average (1.2x)
Price to Sales Ratio vs Fair Ratio
What is IIQ's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||26x|
|Fair PS Ratio||n/a|
Price-To-Sales vs Fair Ratio: Insufficient data to calculate IIQ's Price-To-Sales Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of IIQ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate IIQ's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate IIQ's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is INOVIQ forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as INOVIQ has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
How has INOVIQ performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IIQ is currently unprofitable.
Growing Profit Margin: IIQ is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: IIQ is unprofitable, and losses have increased over the past 5 years at a rate of 38.9% per year.
Accelerating Growth: Unable to compare IIQ's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IIQ is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (-7.9%).
Return on Equity
High ROE: IIQ has a negative Return on Equity (-16.3%), as it is currently unprofitable.
Discover strong past performing companies
How is INOVIQ's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: IIQ's short term assets (A$17.5M) exceed its short term liabilities (A$1.8M).
Long Term Liabilities: IIQ's short term assets (A$17.5M) exceed its long term liabilities (A$690.9K).
Debt to Equity History and Analysis
Debt Level: IIQ is debt free.
Reducing Debt: IIQ had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IIQ has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: IIQ has sufficient cash runway for 2.3 years if free cash flow continues to reduce at historical rates of 30.8% each year.
Discover healthy companies
What is INOVIQ current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|INOVIQ Dividend Yield vs Market|
|Market Bottom 25% (AU)||2.8%|
|Market Top 25% (AU)||7.2%|
|Industry Average (Healthcare)||2.9%|
|Analyst forecast in 3 Years (INOVIQ)||n/a|
Notable Dividend: Unable to evaluate IIQ's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IIQ's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IIQ's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IIQ's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as IIQ has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dr. Leearne Maree Hinch, BSc., B.V.M.S., M.R.C.V.S., M.B.A. has been the Chief Executive Officer of INOVIQ Ltd (formerly known as BARD1 Life Sciences Limited) since November 7, 2016. Dr. Hinch is a biotech...
CEO Compensation Analysis
|Leearne Hinch's Compensation vs INOVIQ Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Jun 30 2022||n/a||n/a|
|Mar 31 2022||n/a||n/a|
|Dec 31 2021||n/a||n/a|
|Sep 30 2021||n/a||n/a|
|Jun 30 2021||AU$867k||AU$330k|
|Mar 31 2021||n/a||n/a|
|Dec 31 2020||n/a||n/a|
|Sep 30 2020||n/a||n/a|
|Jun 30 2020||AU$712k||AU$330k|
|Mar 31 2020||n/a||n/a|
|Dec 31 2019||n/a||n/a|
|Sep 30 2019||n/a||n/a|
|Jun 30 2019||AU$442k||AU$361k|
|Mar 31 2019||n/a||n/a|
|Dec 31 2018||n/a||n/a|
|Sep 30 2018||n/a||n/a|
|Jun 30 2018||AU$403k||AU$359k|
|Mar 31 2018||n/a||n/a|
|Dec 31 2017||n/a||n/a|
|Sep 30 2017||n/a||n/a|
|Jun 30 2017||AU$255k||AU$203k|
Compensation vs Market: Leearne's total compensation ($USD558.78K) is above average for companies of similar size in the Australian market ($USD274.98K).
Compensation vs Earnings: Leearne's compensation has increased whilst the company is unprofitable.
Experienced Management: IIQ's management team is considered experienced (2.2 years average tenure).
Experienced Board: IIQ's board of directors are considered experienced (3.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
|13 May 22||BuyAU$10,620||Philip Powell||Individual||20,000||AU$0.53|
|06 May 22||BuyAU$20,083||Geoffrey Cumming||Individual||32,967||AU$0.61|
|02 May 22||BuyAU$29,000||Philip Powell||Individual||50,000||AU$0.58|
|21 Oct 21||BuyAU$43,671||Philip Powell||Individual||40,000||AU$1.10|
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
INOVIQ Ltd's employee growth, exchange listings and data sources
- Name: INOVIQ Ltd
- Ticker: IIQ
- Exchange: ASX
- Founded: 1983
- Industry: Health Care Services
- Sector: Healthcare
- Implied Market Cap: AU$51.991m
- Shares outstanding: 92.02m
- Website: https://www.inoviq.com
Number of Employees
- INOVIQ Ltd
- 23 Normanby Road
- Notting Hill
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|IIQ||ASX (Australian Securities Exchange)||Yes||Ordinary Shares||AU||AUD||Jun 2016|
|EGQ||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Jun 2016|
|IIQ||CHIA (Chi-X Australia)||Yes||Ordinary Shares||AU||AUD||Jun 2016|
|EGQ0||BST (Boerse-Stuttgart)||Yes||Ordinary Shares||DE||EUR||Jun 2016|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/28 00:00|
|End of Day Share Price||2022/09/28 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.